July 27 (Reuters) - Medical device maker Dexcom Inc (DXCM.O), opens new tab on Thursday raised its annual revenue forecast after strong demand for its continuous glucose monitoring (CGM) systems ...

On Friday, Senseonics, maker of the implantable continuous glucose monitoring system Eversense, announced a new program geared towards patients with high-deductible insurance plans or plans that don’t ...

The first fully implantable continuous glucose monitors can now be integrated with insulin pumps as part of an automated insulin delivery system As the first fully implantable device in the category, ...

AID system compatible with Senseonics Eversense® 365 one-year CGMGERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development ...

With more than 10 years of pioneering CGM market leadership in AID integration, Dexcom is the most studied CGM brand with AID capabilities and the clear choice for powering AID systems 3,4 The ...

With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM’s for minimal life disruption “Managing diabetes can be stressful and it is important for ...

Please provide your email address to receive an email when new articles are posted on . The Tandem Mobi automated insulin delivery system can be integrated with ...

Eligible individuals in the U.S. will pay $99 out of pocket for each 6-month CGM system, offering each year of continuous glucose monitoring for just $200* Eligible individuals will pay only $99 out ...